About the Study

Neuroblastoma: A clinical trial of elfornithine/DFMO and etoposide for relapsed/refractory neuroblastoma

This study is for: • Patients who are between the ages of 0 and 31 years old • Who have been diagnosed with neuroblastoma that has relapsed (has come back) or is refractory (has not responded to earlier treatment) The goal of this study is to find what effects, good and/or bad, the investigational drug eflornithine HCl (difluoromethylornithine DFMO) along with etoposide has on neuroblastoma. An investigational drug is one that has not been approved by the U.S. Food and Drug Administration (FDA). Currently there are no standard of care treatments for patients with neuroblastoma in remission or with relapsed/refractory neuroblastoma. This study will look at the ability of this study drug to either keep the tumors in remission or, if for active tumors, for the tumors to respond to the treatment. The study will also look at the safety and tolerability of DFMO.

Interested in learning more?

Full Study Name: BCC015 Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma